{"analyses":[{"ciLowerLimit":"0.624","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.967","estimateComment":"T+OFS was the reference group in the estimation of the hazard ratio","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.02","paramType":"Hazard Ratio (HR)","paramValue":"0.777","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90.7","upperLimit":"93.1","value":"92.0"},{"groupId":"OG001","lowerLimit":"92.7","upperLimit":"94.8","value":"93.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1328"},{"groupId":"OG001","value":"1332"}],"units":"Participants"}],"description":"Estimated percentage of patients alive and disease-free at 5 years from randomization, where distant recurrence-free interval is defined as the time from randomization to breast cancer recurrence at a distant site; or censored at date of last follow-up","dispersionType":"95% Confidence Interval","groups":[{"description":"Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.","id":"OG000","title":"T+OFS"},{"description":"Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.","id":"OG001","title":"E+OFS"}],"paramType":"NUMBER","populationDescription":"Intention-to-treat","reportingStatus":"POSTED","timeFrame":"5-year estimates reported at a median follow-up of 72 months","title":"Distant Recurrence-free Interval","type":"SECONDARY","unitOfMeasure":"percentage of participants"}